Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cellectar Biosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CLRB
Nasdaq
2834
http://cellectar.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cellectar Biosciences Inc
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update
- May 10th, 2022 12:30 pm
Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia
- Apr 26th, 2022 12:00 pm
Cellectar Biosciences Announces Key Commercial Team Appointments
- Apr 12th, 2022 12:30 pm
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
- Mar 23rd, 2022 10:35 pm
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update
- Mar 21st, 2022 12:30 pm
Cellectar to Participate at Upcoming Banking Conferences
- Mar 10th, 2022 9:05 pm
Cellectar Biosciences Announces Executive Leadership Changes
- Feb 23rd, 2022 1:00 pm
Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?
- Jan 17th, 2022 2:40 pm
Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks
- Jan 17th, 2022 12:40 pm
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
- Jan 14th, 2022 11:27 am
Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
- Jan 4th, 2022 1:30 pm
Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition
- Dec 13th, 2021 1:30 pm
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition
- Dec 8th, 2021 1:30 pm
Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
- Nov 16th, 2021 1:30 pm
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update
- Nov 8th, 2021 1:30 pm
Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer
- Nov 2nd, 2021 12:30 pm
Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies
- Oct 25th, 2021 1:00 pm
Cellectar Biosciences (NASDAQ:CLRB) Is In A Good Position To Deliver On Growth Plans
- Sep 24th, 2021 11:25 am
Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer
- Sep 22nd, 2021 4:27 pm
Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer
- Sep 22nd, 2021 12:30 pm
Scroll